Evidence map›Paper›PMID 42806160›Full record

ArticleThe EMBO journal2026

A functional screen for bacterial ubiquitin regulation identifies an unusual Pseudomonas aeruginosa E3 ligase.

Cameron G Roberts, Supender Kaur, Shun-Je Bhark, Aaron J Ogden, Michael E Divine, Gus D Warren, Donghoon Kang, Natalia V Kirienko, Paul P Geurink, Monique P C Mulder and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Cameron G RobertsDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-0115-7013
Supender KaurDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.
Shun-Je BharkDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.
Aaron J OgdenBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Michael E DivineDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.
Gus D WarrenDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-4822-464X
Donghoon KangDepartment of Biosciences, Rice University, Houston, TX, USA.
Natalia V KirienkoDepartment of Biosciences, Rice University, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1537-4967
Paul P GeurinkDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-1849-1111
Monique P C MulderDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Ernesto S NakayasuBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID http://orcid.org/0000-0002-4056-2695
Jason E McDermottDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.
Joshua N AdkinsBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Alejandro AballayDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.
Jonathan N PrunedaDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA. pruneda@ohsu.edu.ORCID http://orcid.org/0000-0002-0304-4418

Funding

Genetic analysis of innate immunity using C. elegansR37GM070977 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Alejandro Aballay · 2017 to 2026
$3.8M
Exploiting bacterial effector proteins to study human ubiquitin signalingR35GM142486 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jonathan N Pruneda · 2021 to 2026
$2.6M
Mechanism of innate immune activation by intestinal distensionR01AI156900 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABALLAY, ALEJANDRO · 2020 to 2024
$2.0M
Molecular mechanisms for clinical dominance of P. aeruginosa ST111 isolatesR21AI176089 · NIAID · RICE UNIVERSITY · PI KIRIENKO, NATASHA · 2024 to 2025
$414k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI156900HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI176089HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM142486HHS | NIH | National Institute of General Medical Sciences (NIGMS) R37GM070977
6 · The paper itself

Abstract

Bacterial pathogens have adapted secreted effector proteins that hijack host ubiquitination to gain control over host responses. These effectors can exhibit, for example, E3 ligase or deubiquitinase activities, often without any homology to eukaryotic regulators. Such convergence in function poses a challenge to the discovery of additional ubiquitin-targeted virulence factors. Pseudomonas aeruginosa, for example, is a pervasive opportunistic pathogen with numerous mechanisms of virulence, yet no described E3 ligases or deubiquitinases. We have developed a workflow to functionally screen natively secreted bacterial effectors for ubiquitin regulatory activities. After benchmarking this approach on Salmonella Typhimurium, Enteropathogenic Escherichia coli, and Shigella flexneri, we identified a cryptic E3 ligase secreted by P. aeruginosa, which we have termed Pseudomonas Ub ligase 1 (PUL-1). PUL-1 resembles none of the other E3 ligases previously established in or outside of the eukaryotic system. Importantly, in an animal model of P. aeruginosa infection, PUL-1 ligase activity plays an important role in regulating virulence. Thus, functional identification of ubiquitin-targeted effectors can expand our appreciation of ubiquitin regulation during bacterial pathogenesis.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.